Chinook Therapeutics Inc. (NASDAQ: (KDNY) stock surged by 30.39% at last close while the KDNY stock price gains by 2.26% in the after-hours trading session. The company has recently participated in ASN Kidney Week 2021. Chinook Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating kidney disease precision treatments. Chinook’s product candidates are being studied in the treatment of rare, severe chronic renal diseases with well-defined treatment plans.
KDNY stock’ Current Update
Chinook Therapeutics has presented six ePoster presentations at ASN Kidney Week 2021 on the BION-1301 and atrasentan clinical studies. BION-1301 is an anti-APRIL monoclonal antibody that is now in phase 1/2 clinical trials for IgAN patients. Following are the highlights:
- In individuals with IgAN, BION-1301 was well tolerated and showed immediate and sustained decreases in mechanistic indicators such as free APRIL, IgA, and Gd-IgA1 levels.
- After three to six months of treatment, BION-1301 reduced proteinuria by more than half in patients with IgAN, with further reductions in two individuals after a year of treatment.
- Cohort 2 data will be implemented to help determine the subcutaneous dose and schedule that will be employed in later-stage BION-1301 studies.
Alan Glicklich, chief medical officer of Chinook Therapeutics commented,
Their presentations at this year’s ASN Kidney Week on BION-1301 and atrasentan demonstrate their dedication to researching medicines for rare, serious chronic kidney illnesses including IgA nephropathy, a devastating progressing condition for which no approved medications exist. The data they provided on BION-1301 adds to the growing body of evidence that this possibly disease-modifying therapy for patients with IgA nephropathy can produce consistent mechanistic biomarker responses as well as clinically important proteinuria reductions within three months of treatment initiation. They are looking forward to expanding on this intriguing data in the ongoing phase 1/2 study to find the correct subcutaneous dose of BION-1301 to move on into later-stage trials.
